Susan Benjamin

Title: The Innovative Contributions of Susan Benjamin

Introduction

Susan Benjamin is a notable inventor based in Chatillon, France. She has made significant strides in the field of cancer treatment through her innovative research and development. Her work focuses on the combination of inecalcitol with anti-CD38 agents, which has the potential to enhance treatment options for patients suffering from hematological malignancies.

Latest Patents

Susan Benjamin holds a patent for her invention titled "Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer." This patent addresses the use of inecalcitol in conjunction with agents such as daratumumab, MOR 202, or isatuximab. The invention aims to increase or induce the expression of CD-38, thereby improving treatment outcomes for cancer patients.

Career Highlights

Throughout her career, Susan has demonstrated a commitment to advancing medical science. Her work at Hybrigenics S.A. has positioned her as a key player in the development of innovative cancer therapies. With her expertise, she has contributed to the understanding of how inecalcitol can be effectively utilized in cancer treatment.

Collaborations

Susan Benjamin collaborates with talented professionals in her field, including Cécile Planquette and Rémi Delansorne. These partnerships enhance her research efforts and contribute to the overall success of her projects.

Conclusion

Susan Benjamin's contributions to cancer treatment through her innovative patent highlight her dedication to improving patient outcomes. Her work exemplifies the impact of research and collaboration in the medical field.